Kontakt:
Anschrift
Knappschaftskrankenhaus
Klinik für Neurologie
In der Schornau 23-25
D-44892 Bochum
Direktor
Prof. Dr. U. Schlegel
Sekretariat
Tel.: 0234 / 299-3701
Fax.: 0234 / 299-3719
neurologie@kk-bochum.de
Studiensekretariat
Frau Anke Pox
Tel.: 0234 / 299-3703
anke.pox@kk-bochum.de
Frau Bettina Bauert
bettina.bauert@kk-bochum.de
Publikationen von Prof. Dr. med. Uwe Schlegel ab 2000
zurückzur Mitarbeiterübersicht
Eyding J, Wiebringhaus R, Klein FG, Skodda S, Schlegel U, Alekseyev A, Heuser L. (2012): Multimodal CT imaging and recanalizing therapy in acute ischemic stroke - retrospective analysis of a one year single centre experience. Eur Neurol. 2012; 67(4): 193 - 199
Skodda S, Grönheit W, Schlegel U. (2012): Instability of syllable repetition in progressive supranuclear palsy. J Neural Transm. 2012; 119(4): 457 - 462
Schmitz-Hübsch T, Eckert O, Schlegel U, Klockgether T, Skodda S. (2012): Instability of syllable repetition in patients with spinocerebellar ataxia and Parkinson`s disease. Mov Disord. 2012; 27(2): 316 - 319
Sczesni KC, Alekseyev A, Schlegel U, Skodda S. (2012): [Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids]. Nervenarzt 2012; [Epub ahead of print]
Skodda S, Grönheit W, Schlegel U. (2012): Impairment of vowel articulation as a possible marker of disease progression in Parkinson`s disease. PLoS ONE 2012; 7(2): e32132
Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegel W, Hahn S, Schroers R. (2012): Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 2012; 14(1): 29-33
Baraniskin A, Deckert M, Schulte-Altedorneburg G, Schlegel U, Schroers R. (2012): Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol. 2012; 156(4): 421 - 432
Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R. (2011): Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011; 117(11): 3140 - 3146
Skodda S, Visser W, Schlegel U. (2011): Gender-related patterns of dysprosody in Parkinson disease and correlation between speech variables and motor symptoms. J Voice. 2011; 25(1): 76 - 82
Flasskamp A, Kotz SA, Schlegel U, Skodda S. (2011): Acceleration of syllable repetition in Parkinson`s disease is more prominent in the left-side dominant patients. Parkinsonism Relat Disord. 2011; [Epub ahead of print]
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators. (2011): Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM); a randomised, double-blind, parallel-group trial. Lancet. 2011; 377(9782): 2013 - 2022
Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG. (2011): Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger med. Sci. 2011; 9: Doc11
Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, Deangelis LM. (2011): Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous lymphoma. Leukemia. 2011; 25(12): 1797 - 1807
Steinbeck JA, Stuplich M, Blasius E, Pels H, Glas M, Schlegel U, Herrlinger U. (2011): Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy. J Clin Neurosci. 2011; 18(11): 1554 - 1555
Stupp R, Hegi M, Neyns B, Goldbrunner R, Schlegel U, Clement P, Grabenbauer G, Ochsenbein A, Simon M, Dietrich P, Pietsch T, Tonn J, Diserens A, Pica A, Hermisson M, Krueger S, Picard M, Weller M. (2010): Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28(16): 2712 - 2718.
Skodda S, Flasskamp A, Schlegel U. (2010): Instability of syllable repetition as a model for impaired motor processing: is Parkinson's disease a "rhythm disorder"? J Neural Transm. 2010; 117(5): 605 - 612.
Hinkerohe D, Smikalla D, Schoebel A, Haghikia A, Zoidl G, Haase CG, Schlegel U, Faustmann PM. (2010): Dexamethasone prevents LPS-induced microglial activation and astroglial impairment in an experimental bacterial meningitis co-culture model. Brain Res. 2010; 1329: 45 - 54]
Grzendowski M, Wolter M, Riemenschneider MJ, Knobbe CB, Schlegel U, Meyer HE, Reifenberger G, Stühler K. (2010): Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. Neuro Oncol. 2010; 12(3): 243 - 256
Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, Schlegel U. (2010): Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol. 2010; 12(7): 720 - 724
Skodda S, Visser W, Schlegel U. (2010): Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. J Neural Transm. 2010; 117(2): 197 - 205
Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U. (2010): Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol. 2011; 103(3): 635 - 640
Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, Kowoll A, Alekseyev A, Schmiegel W, Schlegel U, Deckert M, Pels H. (2010): Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol. 2010; 85(6): 520 - 528
Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, Schlegel U, Pels H. (2010): Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol. 2010; 85(3): 236 - 242
Hinkerohe D, Wolfkühler D, Haghikia A, Meier C, Faustmann PM, Schlegel U. (2010): Dexamethasone differentially regulates functional membrane properties in glioma cell lines and primary astrocytes in vitro. J Neurooncol. 2011; 103(3): 479 - 489
Skodda S, Visser W, Schlegel U. (2010): Vowel articulation in Parkinson's disease. J Voice. 2011; 25(4): 467 - 472
Fliessbach K, Rogowski S, Hoppe C, Sabel M, Goeppert M, Helmstaedter C, Calabrese P, Schackert G, Tonn JC, Simon M, Schlegel U. (2010): Computer-based assessment of cognitive functions in brain tumor patients. Neurooncol. 2010; 100(3): 427 - 437
Skodda S, Visser W, Schlegel U. (2010): Acoustical analysis of speech in progressive supranuclear palsy. J Voice. 2011; 25(6): 725 - 731
Fischer L, Koch A, Schlegel U, Koch HC, Wenzel R, Schröder N, Thiel E, Korfel A. (2010): Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions. J Neurooncol. 2011; 102(1): 163 - 166
Skodda S, Flasskamp A, Schlegel U. (2010): Instability of syllable repetition as a marker of disease progression in Parkinson's disease: a longitudinal study. Mov Disord. 2011; 26(1): 59 - 64
Skodda S, Grönheit W, Schlegel U. (2010): Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission. J Voice. 2011; 25(4): e199 - 205
Skodda S, Flasskamp A, Schlegel U. (2010): Instability of syllable repetition in Parkinson's disease-influence of levodopa and deep brain stimulation. Mov Disord. 2011; 26(4): 728 - 730
Linnebank M, Moskau S, Jürgens A, Simon M, Semmler A, Orlopp K, Glasmacher A, Bangard C, Vogt-Schaden M, Urbach H, Schmidt-Wolf IG, Pels H, Schlegel U. (2009): Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol 2009; 11(1): 2 - 8
Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, Schmidt-Wolf IG, Schlegel U. (2009): Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009; 91(3): 299 - 305
Calabrese P, Schlegel U. (2009): Neurotoxicity of treatment. Recent Results Cancer Res. 2009; 171: 165 - 174
Schlegel U. (2009): Primary CNS lymphomas. Ther Adv Neurol Disord. 2009; 2(2): 93 - 104
Skodda S, Rinsche H, Schlegel U. (2009): Progression of dysprosody in Parkinson's disease over time--a longitudinal study. Mov Disord 2009; 24(5): 716 - 722
Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U. (2009): Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010; 67(2): 182 - 189
Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A., Nikolova Z. (2009): Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009; 101(12): 1995 - 2004
Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F. (2009): Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol. 2009; 36(4 Suppl 2): 25 - 34
Hoppe C, Fliessbach K, Schlegel U, Elger CE, Helmstaedter C. (2009): NeuroCog FX: computerized screening of cognitive functions in patients with epilepsy. Epilepsy Behav. 2009; 16(2): 298 - 310
Tiemann L, Penner IK, Haupts M, Schlegel U, Calabrese P. (2009): Cognitive decline in multiple sclerosis: impact of topographic lesion distribution on differential cognitive deficit patterns. Mult Scler. 2009; 15(10): 1164 - 1174
Haupts M, Schimrigk S, Brune N, Chan A, Ahle G, Hellwig K, König FB, Schlegel U, Brück W, Gold R. (2008): Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 2008; 255(8): 1272 - 1273
Boes M, Pels H, Klockgether T, Koch A, Schlegel U. (2008): High-grade B-cell NHL of the brachial plexus followed by infiltration of the spinal cord. J Neurol 2008; 255 (1): 135 - 137
Skodda S, Schlegel U. (2008): Speech rate and rhythm in Parkinson's disease. Mov Disord. 2008; 23 (7): 985 - 992
Ahle G, Visser W, Juergens A, Schlegel U. (2008): Successful treatment of hyperventilation-induced nystagmus in vestibular schwannoma with oxcarbacepine. J Neurol 2008; 255(7): 1093
Kowalski T, Maier C, Reinacher-Schick A, Schlegel U. (2008): Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options. Schmerz 2008; 22(1): 16 - 23
Linnebank M, Malessa S, Moskau S, Semmler A, Pels H, Klockgether T, Schlegel U. (2007): Acute methotrexate-induced encephalopathy - causal relation to homozygous allelic state for MTR c.2756A > G (D919G)?. J Chemother. 2007; 19(4): 455 - 457
Becker A, Vezmar S, Linnebank M, Pels H, Bode U, Schlegel U, Jaehde U. (2007): Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int J Clin Pharmacol Ther. 2007; 45(9): 504 - 515
Boes M, Urbach H, Klockgether T, Schlegel U. (2007): Persistent anarthria following mirror infarction in the anterior choroidal artery territory. Eur J Neurol. 2007; 14(4): e6
Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Siemer D, Zühlke-Jenisch R, Pels H, Jürgens A, Schlegel U, Schmidt-Wolf IG, Schaller C, Reifenberger G, Sabel M, Warnecke-Eberz U, Wiestler OD, Küppers R, Siebert R, Deckert M. (2007): Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol. 2007; 66(3): 230 - 237
Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, Linnebank M, Joe A, Bucerius J, Biersack HJ, Pels H. (2006): FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006; 33(2): 164 -168
Grommes C, Landreth G, Sastre M, Beck M, Feinstein DL, Jacobs AH, Schlegel U, Heneka MT. (2006): Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol. 2006; 70(5): 1524 - 1533
Schramm J, Blümcke I, Ostertag CB, Schlegel U, Simon M, Lutterbach J. (2006): Low-grade gliomas - current concepts. Zentralbl Neurochir 2006; 67(2) :55 - 66
Linnebank M, Kemp S, Wanders RJ, Kleijer WJ, van der Sterre ML, Gärtner J, Fliessbach K, Semmler A, Sokolowski P, Köhler W, Schlegel U, Schmidt S, Klockgether T, Wüllner U. (2006): Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy. Neurology 2006; 66(3): 442 - 443
Pels H, Schlegel U. (2006): Primary central nervous system lymphoma. Curr Treat Options Neurol. 2006; 8(4): 346 - 357
Schlegel U, Jürgens A, Pels H. (2006): Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 2006; 66(8): 1287
Linnebank M, Semmler A, Kleijer WJ, van der Sterre ML, Gärtner J, Fliessbach K, Sokolowski P, Köhler W, Schlegel U, Klockgether T, Wanders RJ, Schmidt S, Wüllner U, Kemp S. (2006): The cystathinine beta-synthase variant c.844_845ins68 protects against CNS demyelination in X-linked adrenoleukodystrophy. Hum. Mutat. 2006; 27(10): 1063 - 1064
Fliessbach K, Hoppe C, Schlegel U, Elger CE, Helmstaedter C. (2006): NeuroCogFX--a computer-based neuropsychological assessment battery for the follow-up examination of neurological patients. Fortschr Neurol Psychiatr. 2006; 74:(11) 643 - 650
Orlopp K, Schmidt-Wolf IG, Urbach H, Schlegel U. (2005): Acute central nervous symptoms in oncologic patients. Internist (Berl) 2005; 46(1): 19 - 29
Herrlinger U, Korfel A, Hebart H, Schlegel U, Plasswilm L, Illerhaus G, Finke J, Krüger W, Montemurro M, Wolf T, Thiel E, Bamberg M, Weller M, Kanz L. Centers of Neuro-Oncology and Lymphoma, University of Tübingen, Germany. (2005): Meeting report: primary central nervous system lymphoma: standards of care and future perspectives. Onkologie 2005; 28(2): 109 - 111
Linnebank M, Pels H, Kleczar N, Farmand S, Fliessbach K, Urbach H, Orlopp K, Klockgether T, Schmidt-Wolf IG, Schlegel U. (2005): MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 2005; 64(5): 912 - 913
Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, Schlegel U. (2005): Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005; 64(7): 1184 - 1188
Grommes C, Landreth G, Schlegel U, Heneka MT. (2005): The non-thiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J Pharmacol Exp Ther. 2005; 313(2): 806 - 813
Pels H, Montesinos-Rongen M, Schaller C, Schlegel U, Schmidt-Wolf IG, Wiestler OD, Deckert M. (2005): VH gene analysis of primary CNS lymphomas. J Neurol Sci. 2005; 228(2): 143 - 147
Schmidt S, Schneider T, Schmidt-Wolf IG, Ko Y, Schlegel U, Klockgether T, Hertfelder HJ. (2004): C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b. Mult Scler. 2004; 10(2): 243 - 244
Pels H, Montesinos-Rongen M, Schaller C, Van Roost D, Schlegel U, Wiestler OD, Deckert M. (2004): Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma. Neurology 2004; 63(1): 167 - 169
Harzheim M, Schlegel U, Urbach H, Klockgether T, Schmidt S. (2004): Discriminatory features of acute transverse mylitis: a retrosective analysis of 45 patients. J Neurol Sci. 2004; 217(2): 217 - 223
Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G. (2004): Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 2004; 14(2): 121 - 130
Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, Schmidt-Wolf IG, Glasmacher A, Fliessbach K, Klockgether T, Schlegel U, Pels H. (2004): The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br J Cancer. 2004; 90(10): 1969 - 1971
Fliessbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, Klockgether T, Schmidt-Wolf IG, Schlegel U. (2003): Cognitive performance and magnetic resonance imagine findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol. 2003; 60(4): 563 - 568
Paus S, Urbach H, Klockgether T, Schlegel U. (2003): Meningioma of the optic nerve sheat: treatment with hydroxyurea. J Neurol Neurosurg Psychiatry 2003; 74(9): 1348 - 1350
Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz A, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. (2003): Primary central nervous system lymphoma: results of a pilot/phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003; 21(24): 4489 - 4495
Pels H, Schulz H, Schlegel U, Engert A. (2003): Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003; 26(4): 351 - 354
Schmidt-Wolf IG, Rockstroh JK, Schlegel U, Pels H, Mey U, Strehl J, Weiss R, Huhn D. (2003): Treatment options of AIDS-related lymphoma. Expert Opin Pharmacother. 2003; 4(8): 1331 - 1343
Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbruch T, Schmidt-Wolf IG. (2002): Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol. 2002; 13(4): 629 – 631
Kristof RA, Neuloh G, Hans V, Urbach H, Schlegel U, Simon M, Deckert M, Schramm J. (2002): Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III. J Neurooncol. 2002; 59(3): 231 - 237
Kraus JA, Oster C, Sörensen N, Berthold F, Schlegel U, Tonn JC, Wiestler OD, Pietsch T. (2002): Human medulloblastomas lack point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene. Neuropathol Appl Neurobiol. 2002; 28(2): 136 - 141
Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsknecht J, Heneka MT. (2002): Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem. 2002; 81(5): 1052 - 1060
Zander T, Nettekoven W, Kraus JA, Pels H, Ko YD, Vetter H, Klockgether T, Schlegel U. (2002): Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma. J Neurol. 2002; 249(8): 1055 - 1057
Schmidt-Wolf, IGH.; Rockstroh, JK.; Schlegel, U.; Pels, H.; Weiss, R.; Huhn, D. (2002): New aspects in the treatment of AIDS-related lymphoma. Eur J Med Res. 2002; 7(7): 295 – 303
Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf IG, Helmstaedter C, Fliessbach K, Deckert M, Van Roost D, Fimmers R, Bode U, Klockgether T. (2001): Combined systemic and intraventricular chemotherapy in primary CNS lymphoma : a pilot study. J Neurol Neurosurg Psychiatry 2001; 71(1): 118 – 122
Schlegel U. (2001): The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. Engl J Med. 2001; 344(9): 686 - 687
Jung G, Eisner W, Brandl M, Fraunberger P, Reiffenberger G, Schlegel U, Wiestler OD, Reulen H-J, Wilmanns W. (2001): Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphomcytes: evidence for in situ t-cell activation and therapeutic activity. Int J Cancer 2001; 91(2): 225 – 230
Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U. (2001): Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 2001; 101(4): 311 - 320
Schmidt S, Träber F, Block W, Keller E, Pohl C, von Oertzen J, Schild H, Schlegel U, Klockgether T. (2001): Phenotype assignment in symptomatic female carriers of X-linked adrenoleukodystrophy. J Neurol. 2001; 248(1): 36 - 44
Kraus JA, Wenghoefer M, Glesmann N, Mohr S, Beck M, Schmidt MC, Schröder R, Berweiler U, Roggendorf W, Diete S, Dietzmann K, Heuser K, Muller B, Fimmers R, von Deimling A, Schlegel U. (2001): TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol. 2001; 52(3): 263 – 272
Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K, Heun R. (2000): Plasma 24S-Hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000; 41(2): 195 - 198
Kraus JA, Wenghoefer M, Schmidt MC, von Deimling A, Berweiler U, Roggendorf W, Diete S, Dietzmann K, Müller B, Heuser K, Reifenberger G, Schlegel U. (2000): Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol. 2000; 247(6): 455 – 460
Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U. (2000): Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 2000; 48(2): 89 - 94
Schlegel U, Schmidt-Wolf IG, Deckert M. (2000): Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci. 2000; 181(1-2): 1 – 12
Pels H, Vogt I, Klockgether T, Schlegel U. (2000): Primary non-Hodgkin's lymphoma of the spinal cord. Spine 2000; 25(17): 2262 - 2264
Schlegel U, Schmidt-Wolf IG, Deckert M. (2000): Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci. 2000; 181(1-2): 1 - 12